SG&A Efficiency Analysis: Comparing Novartis AG and Verona Pharma plc

SG&A Efficiency: A Tale of Two Companies

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Novartis AG and Verona Pharma plc have showcased contrasting approaches to SG&A efficiency.

Novartis AG: A Steady Giant

From 2014 to 2023, Novartis AG consistently maintained high SG&A expenses, peaking in 2018. Despite a 24% decrease by 2023, their expenses remained substantial, reflecting their expansive global operations.

Verona Pharma plc: A Rising Contender

Conversely, Verona Pharma plc's SG&A expenses surged by over 2,600% from 2014 to 2023, indicating aggressive growth and expansion strategies. This rapid increase highlights their commitment to scaling operations and market presence.

Conclusion

While Novartis AG exemplifies stability, Verona Pharma plc's dynamic growth strategy offers a fascinating contrast, underscoring diverse paths to success in the pharmaceutical industry.